HUE027110T2 - Aromás-kationos peptid alkalmazása - Google Patents

Aromás-kationos peptid alkalmazása Download PDF

Info

Publication number
HUE027110T2
HUE027110T2 HUE13178043A HUE13178043A HUE027110T2 HU E027110 T2 HUE027110 T2 HU E027110T2 HU E13178043 A HUE13178043 A HU E13178043A HU E13178043 A HUE13178043 A HU E13178043A HU E027110 T2 HUE027110 T2 HU E027110T2
Authority
HU
Hungary
Prior art keywords
peptide
dmt1
dalda
aromatic
use according
Prior art date
Application number
HUE13178043A
Other languages
English (en)
Inventor
Hazel H Szeto
Kesheng Zhao
Peter W Schiller
Original Assignee
Cornell Res Foundation Inc
Clinical Res Inst Of Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc, Clinical Res Inst Of Montreal filed Critical Cornell Res Foundation Inc
Publication of HUE027110T2 publication Critical patent/HUE027110T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)

Claims (12)

  1. Aromis-kationes pepiid alkalmazása Szabadalmi igénypontok
    1. Arpnás-kaílönos peptid iszkémiában szenvedő vagy abból faíépűlö szívszővetben a szív összehúzódást erő növelésében történő alkalmazásra rászoruló alanyban, ahol az aromás-kationos pepiid képlete D-Arg'2W~Omt-tys-Phe-NHs.
  2. 2. Peptid az 1, igénypont szerinti alkalmazásra, ahol a pepiidet az iszkémiás szívszövet reperfúziójávai egyőtt alkaimazzuk,
  3. 3. Peptid: a 2, Igénypont szedné alkalmazásra, ahol az iszkémiás szívszdvet reperfuzsója érpiasztlka, kpszorúér bypass graft vagy trombolítíkus gyógyszerek alkalmazása.
  4. 4. Peptid a 2. Igénypont szedőt! alkalmazásra, aboi a pepiidet koszorúér stenthez adjuk.
  5. 5. Pepiid az 1. igénypont szerinti alkaímazásra, ahol a pepiidet heiyileg vagy szisztémásán adagoljuk.
  6. 6. Peptid az 5. igénypont szerini alkalmazásra, ahol a peptidet intravénásán, orálisan, topikáiisan, intranazáüsan, intramuszkuíánsan, szubkután, transzdermáiisan vagy ionoforézissel adagoljuk,
  7. 7. Aromás-kafionos pepiid iszkémiában szenvedő vagy abbéi felépülő szívszövetben a szív kábujás gátlásában történő alkalmazásra rászoruló alanyban, ahol az aromás-kationos pepiid képlete D'-Arg~216>-Drrd-Lys~Phe-NH2.
  8. 8. Peptid a 7. igénypont szerinti alkalmazásra, ahoi a peptidet az iszkémiás szivszovet reperfúziójávai együtt alkalmazzuk,
  9. 9. Pepiid a 8. igénypont szerinti alkalmazásra, ahol az iszkémiás szívszövet reperfúziója érpiasztlka, koszorúér bypass graft vagy trombolitikus gyógyszerek alkalmazása.
  10. 10. Peptid a 8, igénypont szerinti alkalmazásra, ahoi a peptidet koszorúér stenthez adjuk.
  11. 11. Peptid a 7. igénypont szerinti alkalmazásra, ahol a pepiidet helyileg vagy szisztémásán adagoljuk.
  12. 12. Pepiid a 7. igénypont szerinti alkalmazásra, ahol a pepiidet intravénásán, orálisan, iopikáiisan, inlranazáiisan. intramuszkularisan, szubkután, transzdermálisan vagy ionoforézissel adagoljuk.
HUE13178043A 2003-02-04 2004-02-03 Aromás-kationos peptid alkalmazása HUE027110T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44477703P 2003-02-04 2003-02-04
US53569004P 2004-01-08 2004-01-08

Publications (1)

Publication Number Publication Date
HUE027110T2 true HUE027110T2 (hu) 2016-08-29

Family

ID=32853391

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13178043A HUE027110T2 (hu) 2003-02-04 2004-02-03 Aromás-kationos peptid alkalmazása

Country Status (14)

Country Link
US (8) US7576061B2 (hu)
EP (9) EP3842055A1 (hu)
JP (7) JP4838114B2 (hu)
CN (3) CN102784383B (hu)
AU (1) AU2004209663B2 (hu)
CA (1) CA2515080C (hu)
CY (2) CY1114959T1 (hu)
DK (3) DK2865385T3 (hu)
ES (3) ES2436011T3 (hu)
HK (6) HK1090571A1 (hu)
HU (1) HUE027110T2 (hu)
PT (2) PT1599216E (hu)
SI (1) SI2656854T1 (hu)
WO (1) WO2004070054A2 (hu)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3842055A1 (en) 2003-02-04 2021-06-30 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
CN100506841C (zh) 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
US7550439B2 (en) 2004-01-23 2009-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3549594A1 (en) * 2005-09-16 2019-10-09 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
EP3272353A1 (en) 2008-02-07 2018-01-24 Cornell University Methods for preventing or treating insulin resistance
EP3741381B1 (en) 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
DE102008061044A1 (de) 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
EP3906933A1 (en) * 2009-03-20 2021-11-10 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
EP2464371B1 (en) * 2009-08-12 2016-03-16 Cornell University Methods for preventing or treating metabolic syndrome
EP4302829A3 (en) 2009-08-24 2024-03-27 Stealth BioTherapeutics Inc. Peptide for use in preventing or treating macular degeneration
EP2764871A1 (en) * 2009-10-05 2014-08-13 Cornell University Methods for the prevention or treatment of heart failure
CA2786066A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
EP3269380A1 (en) * 2009-12-31 2018-01-17 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
CN104725472A (zh) * 2010-01-25 2015-06-24 康奈尔大学 芳香族阳离子肽及其用途
CA2790823A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3560508A1 (en) 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110245182A1 (en) 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP2942354A1 (en) * 2010-05-03 2015-11-11 Stealth Peptides International, Inc. Aromatic-Cationic Peptides and Uses of Same
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
EP2590664B1 (en) * 2010-07-09 2019-03-27 Stealth Peptides International, Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
WO2014137496A1 (en) * 2013-03-08 2014-09-12 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20120083452A1 (en) 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
EP2688579A4 (en) * 2011-03-24 2015-10-21 Univ Cornell AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
EP2758411A2 (en) 2011-09-19 2014-07-30 Gencia Corporation Modified creatine compounds
AU2012315586B2 (en) * 2011-09-29 2017-07-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
JP6346092B2 (ja) * 2011-10-17 2018-06-20 コーネル ユニヴァーシティー 芳香族カチオン性ペプチドおよびその使用
EP3466439A1 (en) * 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US9636378B2 (en) * 2012-03-30 2017-05-02 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment neuropathy
AU2013296493B2 (en) * 2012-08-02 2018-04-26 Stealth Biotherapeutics Inc. Methods for treatment of atherosclerosis
US20150246092A1 (en) * 2012-10-22 2015-09-03 Stealth Peptides International, Inc. Methods for reducing risks associated with heart failure and factors associated therewith
DK2961420T3 (da) 2013-03-01 2019-10-07 Stealth Biotherapeutics Corp Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom
EP3673913A1 (en) * 2013-03-01 2020-07-01 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
WO2014174517A1 (en) 2013-04-25 2014-10-30 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2015017781A1 (en) * 2013-08-01 2015-02-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating leber's hereditary optic neuropathy
US20160166633A1 (en) 2013-08-02 2016-06-16 Stealth Bio Therapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
CA2925757A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
WO2015192020A1 (en) 2014-06-13 2015-12-17 Children's Medical Center Corporation Products and methods to isolate mitochondria
ES2869430T3 (es) 2014-06-25 2021-10-25 Flamma Spa Procedimiento para preparar D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida
US10112976B2 (en) 2014-06-30 2018-10-30 Flamma S.P.A. Process for the production of D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN104306954B (zh) * 2014-09-25 2016-08-24 中山大学 Wry三肽在制备治疗阿尔茨海默症药物中的用途
EP3473253A1 (en) 2014-10-29 2019-04-24 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CN115160402A (zh) 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
JP6427691B2 (ja) 2016-11-30 2018-11-21 株式会社ダイセル 撮像装置用レンズモジュール及びその製造方法
EP3606938A1 (en) 2017-04-05 2020-02-12 Stealth BioTherapeutics Corp Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
JP7069295B2 (ja) 2017-08-17 2022-05-17 エックスダブリューファルマ リミテッド 活性酸素種スカベンジャー誘導体の調製および使用
ES2947741T3 (es) 2017-09-04 2023-08-17 Xwpharma Ltd Preparación y uso de un barredor de especies reactivas de oxígeno
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
IL284006B1 (en) * 2018-12-18 2024-08-01 Stealth Biotherapeutics Corp Mitochondria-targeted peptides
WO2020222866A1 (en) * 2019-05-02 2020-11-05 Children's Medical Center Corporation Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CN116390723A (zh) 2020-09-09 2023-07-04 社会利益网络公司 用于将生物素递送至线粒体的方法和组合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0350221B1 (en) 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
DE69129294T2 (de) * 1990-01-17 1998-10-01 The Regents Of The University Of California, Oakland, Calif. Zusammensetzung zur verbesserung der lebenserhaltung biologischer materialien
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
DE69630918T2 (de) * 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6156748A (en) * 1996-10-07 2000-12-05 Eli Lilly And Company Compounds useful as neuro-protective agents
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
EP1071414A1 (en) * 1998-04-24 2001-01-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
CA2386540A1 (en) * 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20020127605A1 (en) * 2000-11-28 2002-09-12 Hamilton Gregory S. Bisubstituted carbocyclic cyclophilin binding compounds and their use
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
MXPA03006666A (es) * 2001-01-25 2004-05-31 Guilford Pharm Inc Compuestos de union de ciclofilina carbociclicos trisubstituidos y su uso.
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US6942681B2 (en) * 2001-02-16 2005-09-13 Cordis Corporation Method of balloon catheter stent delivery system with ridges
JP2004526499A (ja) * 2001-03-16 2004-09-02 エスティーエス バイオポリマーズ，インコーポレイティド 複数層ポリマーコーティングを有する薬物添加ステント
JPWO2002102833A1 (ja) * 2001-06-15 2004-09-30 千寿製薬株式会社 新規エンドモルフィン誘導体
CN100536909C (zh) * 2003-02-04 2009-09-09 科内尔研究基金会 用于防止线粒体通透性改变的方法
EP3842055A1 (en) 2003-02-04 2021-06-30 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
CN100506841C (zh) 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
JP2005005762A (ja) * 2003-06-09 2005-01-06 Fujitsu Ltd 送信電力制御方法及び装置
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
US7550439B2 (en) * 2004-01-23 2009-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3549594A1 (en) 2005-09-16 2019-10-09 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression

Also Published As

Publication number Publication date
PT2656854E (pt) 2015-09-03
CN104225574B (zh) 2017-01-11
JP2015007127A (ja) 2015-01-15
US20100190718A1 (en) 2010-07-29
PT1599216E (pt) 2013-12-17
AU2004209663A1 (en) 2004-08-19
US8404646B2 (en) 2013-03-26
US20070027087A1 (en) 2007-02-01
JP2017095519A (ja) 2017-06-01
EP2865385A1 (en) 2015-04-29
CY1114959T1 (el) 2016-12-14
EP2491943A2 (en) 2012-08-29
HK1131995A1 (en) 2010-02-12
AU2004209663A2 (en) 2004-08-19
JP6126059B2 (ja) 2017-05-10
SI2656854T1 (sl) 2015-09-30
EP3479838A1 (en) 2019-05-08
EP1599216B9 (en) 2015-02-11
EP3144009A1 (en) 2017-03-22
JP5837542B2 (ja) 2015-12-24
WO2004070054A3 (en) 2005-04-14
US7576061B2 (en) 2009-08-18
JP6166312B2 (ja) 2017-07-19
US20150359838A1 (en) 2015-12-17
EP2491943A3 (en) 2013-01-23
JP2013249313A (ja) 2013-12-12
HK1204999A1 (en) 2015-12-11
JP2006516652A (ja) 2006-07-06
CN102784383A (zh) 2012-11-21
DK2865385T3 (en) 2016-12-19
US20040248808A1 (en) 2004-12-09
CA2515080C (en) 2012-04-10
ES2540897T3 (es) 2015-07-14
HK1190930A1 (en) 2014-07-18
CN102784383B (zh) 2014-09-17
HK1090571A1 (en) 2006-12-29
DK2656854T3 (en) 2015-07-06
AU2004209663B2 (en) 2009-01-15
WO2004070054A2 (en) 2004-08-19
EP3305313A1 (en) 2018-04-11
DK1599216T3 (da) 2013-12-09
JP2019089773A (ja) 2019-06-13
EP2491943B1 (en) 2018-10-10
US20120021970A1 (en) 2012-01-26
JP2015180693A (ja) 2015-10-15
EP1599216B1 (en) 2013-11-06
US20130244957A1 (en) 2013-09-19
US20230293624A1 (en) 2023-09-21
HK1178794A1 (en) 2013-09-19
EP2656854B1 (en) 2015-05-20
US8957030B2 (en) 2015-02-17
ES2605504T3 (es) 2017-03-14
EP1599216A4 (en) 2009-11-11
EP2656854A1 (en) 2013-10-30
EP3842055A1 (en) 2021-06-30
JP4838114B2 (ja) 2011-12-14
ES2436011T3 (es) 2013-12-26
CN104225574A (zh) 2014-12-24
EP3659618A1 (en) 2020-06-03
HK1209652A1 (en) 2016-04-08
CY1116575T1 (el) 2017-03-15
US20200038472A1 (en) 2020-02-06
JP5775285B2 (ja) 2015-09-09
US7718620B2 (en) 2010-05-18
JP2011026346A (ja) 2011-02-10
CA2515080A1 (en) 2004-08-19
EP1599216A2 (en) 2005-11-30
EP2865385B1 (en) 2016-11-16
CN102617706A (zh) 2012-08-01

Similar Documents

Publication Publication Date Title
DK2656854T3 (en) Applications of an aromatic-cationic peptide